Loading data for NGNE — first visit, this takes a few seconds.
Neurogene Inc.
35.48 -0.64 (-1.77%)
- Marktkapitalisierung
- $710.0M
- Volumen
- 181K
- Nächster Ergebnistermin
- Nov 12, 2026
Neurogene Inc. (NGNE) Aktienkurs, Analyse & Daten
Innerer Wert
Analystenprognose
Aktienprognosen →Letzte Ergebnisse
| Gemeldet | Vs. Schätzung | YoY-Veränderung | |
|---|---|---|---|
| Umsatz | $0 | n/a | n/a |
| EPS | -$1,53 | -$0,16 | -41.67% |
Kennzahlen
- Geld
- 25.99
- Marktkapitalisierung
- 710M
- Umsatz (TTM)
- n/a
- Nettogewinn (TTM)
- -111M
- 1.96
- -5.04
- n/a
- -6.85
- KBV (TTM)
- 2.59
- KUV (TTM)
- n/a
- Termin Quartalszahlen
- Nov 12, 2026
- Brief
- 44.63
- Volumen
- 181,388
- Ø Vol. (20D)
- 238,896
- Eröffnung
- 36.50
- Vortagesschluss
- 36.12
- Tagesspanne
- 35.38 - 37.64
- 52-Wk Range
- 15.93 - 43.66
- Analyst
- n/a
- Kursziel
- n/a
- Dividenden
- n/a
- Ex-Dividenden-Datum
- n/a
Über Neurogene Inc.
Profil ansehen →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Branche Biotechnology
Sektor Healthcare
IPO Datum Mar 7, 2014
Mitarbeiter 131
Börse NasdaqGM
Tickersymbol NGNE
Website https://www.neurogene.com